GlassScriptPhysician profile
Philip Ceraulo
NPI 1114180882
$1,248.94
in general payments reported to CMS, 2019-2025
19 companies · $438 in 2025
The $438 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.45 · 2020: $146 · 2021: $52.96 · 2022: $177 · 2023: $235 · 2024: $125 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $238.62 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $211.38 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Spr Therapeutics, INC | $160.73 | 2023-2024 | Sprint Pns System |
| Nalu Medical, INC. | $126.62 | 2025 | Nalu Neurostimulation System |
| Nevro Corp. | $100.92 | 2020-2022 | |
| Protega Pharmaceutials INC | $69.54 | 2023 | Roxybond |
| Stimwave Technologies Incorporated | $68.49 | 2022 | |
| Collegium Pharmaceutical, INC. | $44.80 | 2022-2023 | Belbuca |
| Abbvie INC. | $36.78 | 2025 | |
| Zyla Life Sciences, INC. | $36.54 | 2019 | |
| Saluda Medical Americas, INC. | $20.10 | 2023 | Evoke Scs |
| Janssen Pharmaceuticals, INC | $19.18 | 2025 | Spravato |
| Abbott Laboratories | $18.88 | 2025 | Proclaim |
| Forte Bio-Pharma LLC | $17.66 | 2025 | Prolate, Nalocet, Tanlor |
| Valinor Pharma, LLC | $17.11 | 2025 | Movantik |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.14 | 2023 | Relistor |
| Sanofi-Aventis U.S. LLC | $15.77 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.29 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Ceraulo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.